Nav: Home

DNA sequencing determines lymphoma origin, prognosis, Stanford researchers say

November 09, 2016

Sequencing tiny bits of DNA circulating in the blood of patients with lymphoma can accurately identify the cancer subtype and pinpoint mutations that might cause drug resistance, according to researchers at the Stanford University School of Medicine.

This knowledge could help personalize cancer treatment by revealing which patients are likely to be treated successfully and those who may have a poorer prognosis.

Tracking sequence changes over time could also provide a kind of early warning system to identify the emergence of an aggressive form of the cancer by providing a real-time window into tumor evolution. The findings bolster the growing notion that noninvasive, blood-based biopsies of what's known as circulating tumor DNA are likely to transform cancer care.

"Now we can identify the subtype of the tumor, watch how it changes over time and begin to tailor our chemotherapy choices based on the presence or absence of specific mutations," said assistant professor of medicine Ash Alizadeh, MD, PhD. "We've moved beyond just measuring disease burden based on the amount of tumor DNA in the blood."

Alizadeh and assistant professor of radiation oncology Maximilian Diehn, MD, PhD, share senior authorship of the study, which will be published Nov. 9 in Science Translational Medicine. Postdoctoral scholars Florian Scherer, MD, and David Kurtz, MD, and instructor Aaron Newman, PhD, are the lead authors.

Longitudinal study of 92 patients

The researchers conducted a study of 92 prospectively enrolled patients with diffuse large B-cell lymphoma. DLBCL is the most common type of non-Hodgkin lymphoma and is highly biologically variable. As a result, patients vary widely in their response to treatment. About one-third of seemingly successfully treated patients eventually relapse, or their tumors become resistant to treatment. Additionally, a form of indolent B cell lymphoma, which progresses slowly with only mild symptoms, can transform without warning into an aggressive form of the disease.

"This transformation is very difficult to detect, and usually requires an invasive biopsy to diagnose," said Diehn. "Our approach will allow us to monitor patients over time with a simple blood test, and may help us identify transformation much earlier."

The researchers used an enhanced version of a technique they developed called CAPP-Seq to isolate and sequence circulating tumor DNA, or ctDNA, from blood samples from the patients. Unlike previous studies, which tracked lymphoma progression by monitoring the sequence of just one cancer-associated protein, CAPP-Seq can identify a much larger range of mutations in the tumor genome.

They then compared the ctDNA sequences obtained from the patients' stored blood samples with those of the tumor cells from invasive biopsies, and paired the information with what was known about the course of the patient's disease and eventual outcome. They found that low levels of ctDNA after diagnosis but before treatment correlated strongly with progression-free survival in the patients. Those with higher levels of ctDNA faired more poorly overall. Furthermore, they were able to detect the presence of ctDNA in the blood of relapsing patients on average six months before any clinical symptoms appeared and as long as 2.5 years before clinical signs of relapse.

Determining cancer's cell of origin

Perhaps even more importantly, however, the researchers found they could use CAPP-Seq to determine the type of B cell from which the cancer originated and predict prognosis. About two-thirds of people with the germinal center subtype live for five years or more after diagnosis, while those with activated B-cell-like tumors have a poorer prognosis with current treatment regimes. These subtypes are known to predict differential responses to emerging targeted therapies, but they are cumbersome to measure accurately and require biopsies.

Finally, the researchers were able to predict from the ctDNA sequences those patients whose disease was transforming into a much more aggressive form prior to the emergence of clinical symptoms, and even to identify and track specific mutations known to inhibit the response to the targeted therapy with a drug known as ibrutinib.

"In this study we've shown five distinct ways -- by quantifying tumor burden, identifying disease subtype, cataloging mutations, predicting transformation and providing early warnings of recurrence -- that circulating tumor DNA can yield potentially clinically useful information," said Diehn. "Now we're eager to conduct prospective studies in recently diagnosed patients to learn how we can best improve patient care."

Alizadeh and Diehn are both investigators at the Ludwig Center for Cancer Stem Cell Research and Medicine at Stanford.

The team's work is an example of Stanford Medicine's focus on precision health, the goal of which is to anticipate and prevent disease in the healthy and precisely diagnose and treat disease in the ill.
-end-
Other Stanford co-authors of the study are research associates Henning Stehr, PhD, and Chih Long Liu, PhD; former research assistant Alexander Craig; postdoctoral scholars Mohammad Esfahani, PhD, and Daniel Klass, PhD; former postdoctoral scholar Alexander Lovejoy, PhD; graduate student Jacob Chabon; research assistant Li Zhou; clinical trials assistant Cynthia Glover; assistant professor of surgery Brendan Visser, MD; associate professor of surgery George Poultsides, MD; professor of medicine Ranjana Advani, MD; clinical assistant professor of medicine Lauren Maeda, MD; clinical assistant professor of medicine Neel Gupta, MD; professor of medicine Ronald Levy, MD; assistant professor of pathology Robert Ohgami, MD, PhD; and clinical assistant professor of pathology Christian Kunder, MD, PhD.

Newman, Klass and Alizadeh are co-inventors on patent applications related to CAPP-Seq, and Newman, Diehn and Alizadeh are consultants for Roche Molecular Systems. Lovejoy and Klass are currently employed by Roche Molecular Systems.

The research was supported by the Damon Runyon Cancer Research Foundation, the American Society of Hematology, the V Foundation for Cancer Research, the German Research Foundation, the Stanford TRAM Pilot Grant, the American Society of Clinical Oncology and the National Institutes of Health (grants K99CA187192, R01CA188298, and 1DP2CA186569).

Stanford's departments of Medicine and of Radiation Oncology also supported the work.

The Stanford University School of Medicine consistently ranks among the nation's top medical schools, integrating research, medical education, patient care and community service. For more news about the school, please visit http://med.stanford.edu/school.html. The medical school is part of Stanford Medicine, which includes Stanford Health Care and Lucile Packard Children's Hospital Stanford. For information about all three, please visit http://med.stanford.edu.

Stanford University Medical Center

Related Cancer Articles:

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
More Cancer News and Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...